With the upcoming patent expiration of therapeutic antibodies, the development of generic drug substances is a growing field.

Recombinant production processes may impact various parameters of biopharmaceuticals:

  • Glycosylation pattern
  • Amino acid substitutions
  • Folding/misfolding
  • Disulfide bridging and pairing
  • N-terminal glutamine cyclization
  • Clipping
  • Deamidation (Asn -> Asp; Gln -> Glu; loss of epsilon-NH2 on Lys)
  • Oxidation (Met, His, Trp)

Proteome Factory offers many services for this challenging field:

Popular requests are:

Erythropoeitin (EPO), Darbepoetin (dEPO), Cetuximab (Erbitux™), Trastuzumab (Herceptin™), Infliximab (Remicade™), Natalizumab (Tysabri™) among others: Adalimumab, Aflibercept, Alemtuzumab, Basiliximab, Bevacizumab, Brentuximab, Canakinumab, Denosumab, Etanercept, Factor VIII, G-CSF, Golimumab, Ipilimumab, Mogamulizumab, Omalizumab, Pertuzumab, Ranibizumab, Rilonacept, Tocilizumab, Ustekinumab.

All trademarks mentioned herein belong to their respective owners.